SCICLONE'S ZADAXIN(R) THYMOSIN ALPHA 1 IN COMBINATION WITH TACE IMPROVED SURVIVAL OF LIVER CANCER PATIENTS, STUDY FINDS SAN MATEO, Calif., March 27 /PRNewswire-Asianet/ -- SciClone Pharmaceuticals (Nasdaq: SCLN), today announced the results of a study published in Hepato-Gastroenterology 45 (1998) indicating that its lead product, ZADAXIN(R) thymosin alpha 1, may be useful in the treatment of hepatocellular carcinoma (HCC), the most common cancer worldwide. The ZADAXIN plus transcatheter arterial chemoembolization (TACE) combination regimen "resulted in a longer survival that reached statistical significance seven months after the end of treatment (p